{"id":111,"date":"2024-06-26T13:54:39","date_gmt":"2024-06-26T13:54:39","guid":{"rendered":"https:\/\/www.merckvaccines.com\/vaxneuvance\/?page_id=111"},"modified":"2025-12-22T11:10:21","modified_gmt":"2025-12-22T11:10:21","slug":"safety-tolerability","status":"publish","type":"page","link":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/","title":{"rendered":"Safety tolerability"},"content":{"rendered":"\n\n
<\/div>\"\"<\/picture>

Key safety and tolerability data for VAXNEUVANCE<\/strong><\/h1>

<\/p>

<\/div>
<\/div><\/div><\/div><\/div>
<\/div><\/div>\n\n\n\n\n
<\/div>\n\n\n\n\n

Most commonly reported adverse reactions<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n\n
\n\n

Most commonly reported solicited adverse reactions in children vaccinated with a 4-dose series at 2, 4, 6, and 12 through 15 months <\/strong>of age, provided as a range across the series<\/p>\n\n\n

<\/div>\n\n<\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n\n\n
Adverse reactions<\/strong><\/th>Range across series<\/strong><\/th><\/tr><\/thead>
Irritability<\/td>57.3% – 63.4%<\/td><\/tr>
Somnolence<\/td>24.2% – 47.5%<\/td><\/tr>
Injection-site pain<\/td>25.9% – 40.3%<\/td><\/tr>
Fever \u226538.0\u00b0C<\/td>13.3% – 20.4%<\/td><\/tr>
Decreased appetite<\/td>14.1% – 19.0%<\/td><\/tr>
Injection-site induration<\/td>13.2% – 15.4%<\/td><\/tr>
Injection-site erythema<\/td>13.7% – 21.4%<\/td><\/tr>
Injection-site swelling<\/td>11.3% – 13.4%<\/td><\/tr><\/tbody><\/table>
<\/small><\/div><\/figure>\n\n\n\n\n
\n<\/div>\n\n\n\n
\n
\n

Most commonly reported solicited adverse reactions in children and adolescents 2 through 17 years <\/strong>of age vaccinated with a single dose
<\/p>\n\n\n\n

<\/div>\n<\/div><\/div><\/div><\/div>\n\n\n\n
<\/div>\n\n\n\n
Adverse reactions<\/strong><\/strong><\/th>Single dose<\/strong><\/strong><\/th><\/tr><\/thead>
Injection-site pain<\/td>54.8%<\/td><\/tr>
Myalgia<\/td>23.7%<\/td><\/tr>
Injection-site swelling<\/td>20.9%<\/td><\/tr>
Injection-site erythema<\/td>19.2%<\/td><\/tr>
Fatigue<\/td>15.8%<\/td><\/tr>
Headache<\/td>11.9%<\/td><\/tr>
Injection-site induration<\/td>6.8%<\/td><\/tr><\/tbody><\/table>
<\/small><\/div><\/figure>\n\n\n\n
\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
<\/div>\n\n\n\n

Comparable safety profile to PCV13<\/strong><\/h2><\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

The safety profile of VAXNEUVANCE was comparable to that of PCV13 in clinical trials of both healthy children and those at increased risk for IPD.a<\/sup><\/p>\n<\/div>\n\n\n\n

\n

The safety profile of a series initiated with PCV13 and completed with VAXNEUVANCE was similar to the safety profile following a complete 4-dose regimen of either vaccine.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n

a<\/sup>Pediatric populations with risk conditions were preterm infants, children living with HIV or SCD (immunocompromising diseases), or children who had received an allo-HSCT (an immunocompromising condition): preterm infants, <37 weeks gestation at birth; children living with HIV, 6\u201317 years of age; children living with SCD, 5\u201317 years of age; and recipients of allo-HSCT, 3\u201317 years of age.<\/p>\n\n\n\n

<\/div>\n\n\n\n

Allo-HSCT, allogeneic hematopoietic stem cell transplant; HIV, human immunode\ufb01ciency virus; IPD, invasive pneumococcal disease; PCV13, 13-valent pneumococcal conjugate vaccine; SCD, sickle cell disease.<\/p>\n\n\n\n

<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/i><\/div>

See details on reimbursement<\/strong><\/h3>

See details on reimbursement<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n
<\/i><\/div>

Discover resources for your practice <\/strong><\/h3>

Discover resources for your practice <\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
<\/i><\/div>

See dosage & administration for VAXNEUVANCE<\/strong><\/h3>

See dosage & administration for VAXNEUVANCE<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n\n\n\n
\n
<\/i><\/div>

Review CDC, AAP, and AAFP recommendations<\/strong><\/h3>

Review CDC, AAP, and AAFP recommendations<\/a><\/p><\/div>

<\/i><\/div><\/div><\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n\n
ExternalSitePopup<\/span><\/div>
<\/i><\/a>

By clicking on this link, you will be leaving Merck Vaccines.<\/h2><\/div>
<\/div>
Cancel<\/a><\/div>
Proceed<\/a><\/div><\/div><\/div><\/div>
Cancel<\/a><\/div>
Proceed<\/a><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

The safety profile of VAXNEUVANCE was comparable to that of PCV13 in clinical trials of both healthy children and those at increased…<\/p>\n","protected":false},"author":708,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_trash_the_other_posts":false,"editor_notices":[],"footnotes":""},"ga4_page_audience":[1166],"ga4_page_birn_id":[],"ga4_page_branding":[227],"ga4_page_businessunit":[235],"ga4_page_campaign":[],"ga4_page_content_purpose":[276],"ga4_page_customer_journey_stage":[296],"ga4_page_customer_specialty":[359],"ga4_page_experience":[],"ga4_page_indication":[1215],"ga4_page_material_intent":[575],"ga4_page_product":[777],"ga4_page_region":[1025],"ga4_page_therapeuticarea":[1120],"class_list":["post-111","page","type-page","status-publish"],"yoast_head":"\nSafety and Tolerability Profiles for VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine)<\/title>\n<meta name=\"description\" content=\"HCPs can learn more about the safety and tolerability profile of VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including potential adverse reactions. %\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Safety and Tolerability Profiles for VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine)\" \/>\n<meta property=\"og:description\" content=\"HCPs can learn more about the safety and tolerability profile of VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including potential adverse reactions. %\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/\" \/>\n<meta property=\"og:site_name\" content=\"vaxneuvance-pediatric-mv\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-22T11:10:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2024\/08\/Safety-and-Tol-Header_NEW_Desktop.webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Safety and Tolerability Profiles for VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine)","description":"HCPs can learn more about the safety and tolerability profile of VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including potential adverse reactions. %","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/","og_locale":"en_US","og_type":"article","og_title":"Safety and Tolerability Profiles for VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine)","og_description":"HCPs can learn more about the safety and tolerability profile of VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including potential adverse reactions. %","og_url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/","og_site_name":"vaxneuvance-pediatric-mv","article_modified_time":"2025-12-22T11:10:21+00:00","og_image":[{"url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2024\/08\/Safety-and-Tol-Header_NEW_Desktop.webp","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/","name":"Safety and Tolerability Profiles for VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine)","isPartOf":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/#primaryimage"},"image":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/#primaryimage"},"thumbnailUrl":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2024\/08\/Safety-and-Tol-Header_NEW_Desktop.webp","datePublished":"2024-06-26T13:54:39+00:00","dateModified":"2025-12-22T11:10:21+00:00","description":"HCPs can learn more about the safety and tolerability profile of VAXNEUVANCE\u00ae (Pneumococcal 15-valent Conjugate Vaccine) for appropriate patients, including potential adverse reactions. %","breadcrumb":{"@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/#primaryimage","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2024\/08\/Safety-and-Tol-Header_NEW_Desktop.webp","contentUrl":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-content\/uploads\/sites\/173\/2024\/08\/Safety-and-Tol-Header_NEW_Desktop.webp","width":1145,"height":279},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/safety-tolerability\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckvaccines.com\/vaxneuvance\/"},{"@type":"ListItem","position":2,"name":"Safety tolerability"}]},{"@type":"WebSite","@id":"https:\/\/www.merckvaccines.com\/vaxneuvance\/#website","url":"https:\/\/www.merckvaccines.com\/vaxneuvance\/","name":"vaxneuvance-pediatric-mv","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckvaccines.com\/vaxneuvance\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/111","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/users\/708"}],"replies":[{"embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/comments?post=111"}],"version-history":[{"count":77,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/111\/revisions"}],"predecessor-version":[{"id":2921,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/pages\/111\/revisions\/2921"}],"wp:attachment":[{"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/media?parent=111"}],"wp:term":[{"taxonomy":"ga4_page_audience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_audience?post=111"},{"taxonomy":"ga4_page_birn_id","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_birn_id?post=111"},{"taxonomy":"ga4_page_branding","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_branding?post=111"},{"taxonomy":"ga4_page_businessunit","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_businessunit?post=111"},{"taxonomy":"ga4_page_campaign","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_campaign?post=111"},{"taxonomy":"ga4_page_content_purpose","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_content_purpose?post=111"},{"taxonomy":"ga4_page_customer_journey_stage","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_customer_journey_stage?post=111"},{"taxonomy":"ga4_page_customer_specialty","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_customer_specialty?post=111"},{"taxonomy":"ga4_page_experience","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_experience?post=111"},{"taxonomy":"ga4_page_indication","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_indication?post=111"},{"taxonomy":"ga4_page_material_intent","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_material_intent?post=111"},{"taxonomy":"ga4_page_product","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_product?post=111"},{"taxonomy":"ga4_page_region","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_region?post=111"},{"taxonomy":"ga4_page_therapeuticarea","embeddable":true,"href":"https:\/\/www.merckvaccines.com\/vaxneuvance\/wp-json\/wp\/v2\/ga4_page_therapeuticarea?post=111"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}